Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.

ABSTRACT:

Background

Previous studies suggested increased mortality in patients with hepatorenal syndrome type 1 (HRS1) and advanced acute-on-chronic liver failure (ACLF).

Aim

To assess mortality and respiratory failure (RF) in patients with HRS1 and ACLF treated with terlipressin.

Methods

In the CONFIRM study, we randomised 299 patients with HRS1 2:1 to terlipressin or placebo, both with albumin. At enrolment, all patients were assessed for organ failure (OF) using a validated ACLF grading system. Post hoc analyses assessed the effects of terlipressin vs. placebo on the incidence of RF and 90-day mortality.

Results

The incidence of RF with terlipressin (n = 200) was 9.4% in patients with grades 1-2 ACLF, and 30% with grade 3 ACLF (p = 0.0002); no such difference was obs

SUBMITTER: Wong F 

PROVIDER: S-EPMC9804971 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature